Medtronic plc to acquire CathWorks for up to $585M, bringing AI FFRangio into cath labs

Medtronic to acquire CathWorks, pushing AI diagnostics into cath labs

GALWAY, Ireland, Feb. 3 (Reuters) — Medtronic plc announces it will exercise its option to acquire privately held CathWorks, advancing a relationship that began with a 2022 strategic partnership and co‑promotion agreement for the FFRangio® System. The deal is valued at up to $585 million, plus potential undisclosed post‑close earn‑out payments, and follows commercial availability of the technology in the United States, Europe and Japan. Medtronic frames the move as part of a broader effort to expand its cardiovascular pipeline and strengthen its interventional cardiology offerings.

AI‑driven physiology mapping aims to change cath lab workflows

Medtronic says the acquisition centers on the FFRangio System, which uses artificial intelligence and advanced computational science to produce a comprehensive physiological assessment of the entire coronary tree from routine coronary angiograms. The company highlights that FFRangio addresses limitations of wire‑based fractional flow reserve — an invasive measurement that needs pressure wires and pharmacologic hyperemia and yields values at a single location. Jason Weidman, senior vice president and president of Medtronic’s Coronary & Renal Denervation business, says co‑promotion experience shows the FFRangio system can disrupt traditional wire‑based FFR by leveraging data and AI to provide real‑time information that supports individualized patient pathways from diagnosis to treatment.

Medtronic positions the technology as a way to transform decision making in the cath lab by delivering broader physiologic mapping that informs revascularization choices, with the goal of avoiding unnecessary percutaneous coronary interventions and improving outcomes. The company points to clinical studies that demonstrate FFRangio’s diagnostic accuracy and “promising” clinical outcomes, asserting that integrating less invasive, data‑driven diagnostics into its therapeutic portfolio will accelerate innovation in cath lab workflows and scale access across hospitals and health systems.

Commercial footprint and next steps

FFRangio is already commercially available in key markets, and Medtronic says the acquisition will enable wider rollout through its global distribution and service channels. The company expects to fold the technology into existing interventional cardiology offerings and to leverage clinical evidence from ongoing studies to support adoption.

Clinical implications for coronary care

Industry observers note that wire‑based FFR, despite evidence of benefit, remains underused because of invasiveness and workflow burdens. Medtronic argues that a non‑wire, AI‑based mapping system could lower barriers to physiologic assessment, change revascularization practices and influence standards of care for coronary artery disease.